AbbVie’s shares dropped after releasing an update on the company’s Phase III B-cell lymphoma trial.

Pfizer’s Xalkori, the first drug approved in the United States for patients with ALK-positive and ROS1-positive non-small cell lung cancer, secured Breakthrough Therapy Designation from the U.S. FDA for two new indications.

AbbVie, a research-based global biopharmaceutical company, announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival.

Shares of Celgene plunged after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.

The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.

Novartis’s new gene-modifying cancer therapy’s $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.

Gilead Sciences agreed to buy Kite Pharma in a nearly $12 billion deal as it looks to replace flagging sales from hepatitis C drugs via cancer immunotherapies.

Tazemetostat – an experimental Phase II treatment for lymphomas – showed a 29 percent overall response rate in patients with DLBCL, below investors’ expectations.

Gazyva combined with chemotherapy failed to meet its primary endpoints in a Phase III trial for patients with previously untreated diffuse large B-cell lymphoma.

Johnson & Johnson’s and AbbVie’s cancer drug Imbruvica significantly reduced the risk of death and disease progression compared with chemotherapy in previously untreated patients with a type of leukemia in a late stage study, paving the way for an expanded approval of the medicine. In the trial of 269 patients aged 65 and older with […]